Hens Hatching Hope

September 8, 2026 updated by: Ana Palacios, Georgia Southern University

Program Evaluation: Eggs Hatching Hope. Providing Egg Vouchers to Women With Young Children in Rural Honduras.

The study is a prospective community-cluster non-randomized trial that will evaluate the effectiveness of a program that will provide 30-day egg vouchers to mothers of 6 to 24 month-old children living in rural areas of Intibucá, Honduras.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ana Palacios, MD, PhD
  • Phone Number: 4193244643
  • Email: anapalac@iu.edu

Study Locations

  • Honduras
    • Intibucá Department
      • Concepción, Intibucá Department, Honduras

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 2 years (Child)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy children ages 6 to 24 months at the time the study begins
  • No cerebral palsy, birth defect or condition that may affect their growth or development.
  • Children living in the department of Intibucá, Honduras

Exclusion Criteria:

  • Children from families that are considering leaving the region within the next 12 months
  • Known egg allergy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
30-day egg vouchers, in addition to the standard of care.
Other: Egg vouchers
30-day egg vouchers will be provided monthly, in addition to standard of care.
Other: Standard of Care
Participants will continue to receive the standard of care. No egg vouchers.
Active Comparator: Control group
Standard of care.
Other: Standard of Care
Participants will continue to receive the standard of care. No egg vouchers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Length/Height-for-age z-scores (zHAZ) from baseline at 6 months
Time Frame: 6 months
Calculated using the 2006 World Health Organization Child Growth Standards
6 months
Changes in Length/Height-for-age z-scores (zHAZ) from baseline at 12 months
Time Frame: Change from baseline zHAZ at 12 months
Calculated using the 2006 World Health Organization Child Growth Standards
Change from baseline zHAZ at 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in the prevalence of stunting from baseline at 6 months
Time Frame: 6 months
Calculated using the 2006 World Health Organization Child Growth Standards (zHAZ <-2)
6 months
Changes in the prevalence of stunting from baseline at 12 months
Time Frame: 12 months
Calculated using the 2006 World Health Organization Child Growth Standards (zHAZ <-2)
12 months
Changes in the prelavence of underweight (Weight-for-age z-score <-2) from baseline at 6 months
Time Frame: 6 months
Calculated using the 2006 World Health Organization Child Growth Standards
6 months
Changes in the prelavence of underweight (Weight-for-age z-score <-2) from baseline at 12 months
Time Frame: 12 months
Calculated using the 2006 World Health Organization Child Growth Standards
12 months
Assessment of rapid weight gain after 6 months of intervention
Time Frame: 6 months
Defined as a zBMI upward percentile crossing (>+0.67 SD) Calculated using the 2006 World Health Organization Child Growth Standards
6 months
Assessment of rapid weight gain after 12 months of intervention
Time Frame: 12 months
Defined as a zBMI upward percentile crossing (>+0.67 SD) Calculated using the 2006 World Health Organization Child Growth Standards
12 months
Changes in the prevalence of diarrhea from baseline at 12 months
Time Frame: 12 months
Defined as three or more liquid or semisolid stools in 24 hours
12 months
Changes in the prevalence of Respiratory symptoms from baseline at 12 months
Time Frame: 12 months
Defined as reported presence of cough, or nasal congestion, or ear ache, or sore throat in the last 7 days.
12 months
Changes in the prevalence of Respiratory infections from baseline at 12 months
Time Frame: baseline and 12 months
Defined as reported presence of fever + any of the following symptoms: cough, or nasal congestion, or ear ache, or sore throat in the last 7 days
baseline and 12 months
Changes in the food insecurity scores from baseline at 6 months
Time Frame: 6 months
Measured using the 2012 Latin American and Caribbean scale of Food insecurity (Escala Latinoamercana y Caribeña de Seguridad Alimentaria)
6 months
Changes in the food insecurity scores from baseline at 12 months
Time Frame: 12 months
Measured using the 2012 Latin American and Caribbean scale of Food insecurity (Escala Latinoamercana y Caribeña de Seguridad Alimentaria)
12 months
Changes in the dietary diversity scores from baseline at 6 months
Time Frame: 6 months
Measured using the frequency of intake survey from the 2012 Latin American and Caribbean scale of Food insecurity (Escala Latinoamercana y Caribeña de Seguridad Alimentaria)
6 months
Changes in the dietary diversity scores from baseline at 12 months
Time Frame: 12 months
Measured using the frequency of intake survey from the 2012 Latin American and Caribbean scale of Food insecurity (Escala Latinoamercana y Caribeña de Seguridad Alimentaria)
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Georgia Southern University

Collaborators

Shoulder to Shoulder

Investigators

  • Principal Investigator: Ana Palacios, MD, PhD, Indiana University, Bloomington

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 23, 2021

Primary Completion (Estimated)

April 30, 2029

Study Completion (Estimated)

April 30, 2029

Study Registration Dates

First Submitted

January 18, 2021

First Submitted That Met QC Criteria

January 21, 2021

First Posted (Actual)

January 22, 2021

Study Record Updates

Last Update Posted (Actual)

September 9, 2026

Last Update Submitted That Met QC Criteria

September 8, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2012965659

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe